CareDx (CDNA)
(Delayed Data from NSDQ)
$15.94 USD
+0.11 (0.69%)
Updated May 24, 2024 04:00 PM ET
After-Market: $15.95 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
CDNA 15.94 +0.11(0.69%)
Will CDNA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CDNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDNA
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
CDNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
How CareDx (CDNA) Stock Stands Out in a Strong Industry
Other News for CDNA
Top 3 Health Care Stocks That May Crash In May
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)
CareDx price target raised by $7 at Craig-Hallum, here's why
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
Balanced Outlook for CareDx: Strong Performance Amid Rising Competition